Novel endogenous angiogenesis inhibitors and their therapeutic potential
Citations Over TimeTop 10% of 2015 papers
Abstract
Angiogenesis, the formation of new blood vessels from the pre-existing vasculature is essential for embryonic development and tissue homeostasis. It also plays critical roles in diseases such as cancer and retinopathy. A delicate balance between pro- and anti-angiogenic factors ensures normal physiological homeostasis. Endogenous angiogenesis inhibitors are proteins or protein fragments that are formed in the body and have the ability to limit angiogenesis. Many endogenous angiogenesis inhibitors have been discovered, and the list continues to grow. Endogenous protein/peptide inhibitors are relatively less toxic, better tolerated and have a lower risk of drug resistance, which makes them attractive as drug candidates. In this review, we highlight ten novel endogenous protein angiogenesis inhibitors discovered within the last five years, including ISM1, FKBPL, CHIP, ARHGAP18, MMRN2, SOCS3, TAp73, ZNF24, GPR56 and JWA. Although some of these proteins have been well characterized for other biological functions, we focus on their new and specific roles in angiogenesis inhibition and discuss their potential for therapeutic application.
Related Papers
- → Angiogenesis Inhibition by Angiostatin, Endostatin and TNP-470 Prevents Cyclophosphamide Induced Cystitis(2004)13 cited
- → An In Vivo Angiogenesis Assay to Study Positive and Negative Regulators of Neovascularization(2003)4 cited
- → Modulation of Angiogenesis: Experimental Strategies and Potential Therapeutic Applications(2003)2 cited
- The Mechanism of Endostatin in the Angiogenesis Related Disease(2005)